Johnson & Johnson (FRA:JNJ)
173.82
+0.32 (0.18%)
At close: Dec 5, 2025
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.99B USD in the quarter ending September 28, 2025, with 6.77% growth. This brings the company's revenue in the last twelve months to $92.15B, up 5.08% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$92.15B
Revenue Growth
+5.08%
P/S Ratio
5.31
Revenue / Employee
$667.26K
Employees
138,100
Market Cap
418.20B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Johnson & Johnson News
- 17 hours ago - JNJ releases new data bolstering Inlexzo for bladder cancer - Seeking Alpha
- 18 hours ago - Johnson & Johnson's (JNJ) SunRISe-1 Study Shows Promising Results for Bladder Cancer Treatment - GuruFocus
- 18 hours ago - Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC - PRNewsWire
- 1 day ago - Guggenheim Raises Price Target for JNJ to $227, Maintains 'Buy' Rating | JNJ Stock News - GuruFocus
- 1 day ago - Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi - Nasdaq
- 1 day ago - Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note - Nasdaq
- 1 day ago - Johnson & Johnson at Citi Global Healthcare Conference Transcript - GuruFocus
- 2 days ago - Johnson & Johnson Named Top Dividend Stock With Insider Buying and 2.53% Yield (JNJ) - Nasdaq